Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand.

Sánchez-Vargas LA, Kounlavouth S, Smith ML, Anderson KB, Srikiatkhachorn A, Ellison DW, Currier JR, Endy TP, Mathew A, Rothman AL.

Front Immunol. 2019 Jun 13;10:1359. doi: 10.3389/fimmu.2019.01359. eCollection 2019.

2.

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.

Moris P, Bauer KM, Currier JR, Friberg H, Eckels KH, Esquilin IO, Gibbons RV, Innis BL, Jarman RG, Simasathien S, Sun P, Thomas SJ, Watanaveeradej V.

Hum Vaccin Immunother. 2019 Mar 4:1-16. doi: 10.1080/21645515.2019.1581536. [Epub ahead of print]

PMID:
30829100
3.

Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection.

Friberg H, Beaumier CM, Park S, Pazoles P, Endy TP, Mathew A, Currier JR, Jarman RG, Anderson KB, Hatch S, Thomas SJ, Rothman AL.

PLoS Negl Trop Dis. 2018 Dec 17;12(12):e0006975. doi: 10.1371/journal.pntd.0006975. eCollection 2018 Dec.

4.

Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.

Adam A, Woda M, Kounlavouth S, Rothman AL, Jarman RG, Cox JH, Ledgerwood JE, Gromowski GD, Currier JR, Friberg H, Mathew A.

J Immunol. 2018 Dec 15;201(12):3804-3814. doi: 10.4049/jimmunol.1800892. Epub 2018 Nov 9.

PMID:
30413671
5.

Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination.

Costanzo MC, Kim D, Creegan M, Lal KG, Ake JA, Currier JR, Streeck H, Robb ML, Michael NL, Bolton DL, Steers NJ, Eller MA.

Nat Commun. 2018 Mar 23;9(1):1212. doi: 10.1038/s41467-018-03618-w.

6.

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.

McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, Eckles KH, Garver LS, Boyd M, Jetton D, Barouch DH, Wise MC, Lewis BS, Currier JR, Modjarrad K, Milazzo M, Liu M, Mullins AB, Putnak JR, Michael NL, Jarman RG, Thomas SJ.

PLoS Pathog. 2017 Aug 3;13(8):e1006487. doi: 10.1371/journal.ppat.1006487. eCollection 2017 Aug.

7.

Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions.

Woda M, Friberg H, Currier JR, Srikiatkhachorn A, Macareo LR, Green S, Jarman RG, Rothman AL, Mathew A.

J Infect Dis. 2016 Oct 1;214(7):1001-9. doi: 10.1093/infdis/jiw308. Epub 2016 Jul 20.

8.

Analysis of cell-mediated immune responses in support of dengue vaccine development efforts.

Rothman AL, Currier JR, Friberg HL, Mathew A.

Vaccine. 2015 Dec 10;33(50):7083-90. doi: 10.1016/j.vaccine.2015.09.104. Epub 2015 Oct 14. Review.

PMID:
26458801
9.

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.

Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H, Danko JR, Teneza-Mora NC, Putnak JR, Eckels KH, Thomas SJ.

Am J Trop Med Hyg. 2015 Sep;93(3):454-460. doi: 10.4269/ajtmh.14-0819. Epub 2015 Jul 6.

10.

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

Ratto-Kim S, de Souza MS, Currier JR, Karasavvas N, Sidney J, Rolland M, Valencia-Micolta A, Madnote S, Sette A, Nitayaphan S, Pitisuttuthum P, Kaewkungwal J, Rerks-Ngarm S, O'Connell R, Michael N, Robb ML, Marovich M, Kim JH.

PLoS One. 2015 Feb 9;10(2):e0115582. doi: 10.1371/journal.pone.0115582. eCollection 2015.

11.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. doi: 10.1073/pnas.1400446111. Epub 2014 Sep 2.

12.

Immunopathogenesis Versus Protection in Dengue Virus Infections.

Rothman AL, Medin CL, Friberg H, Currier JR.

Curr Trop Med Rep. 2014 Mar 1;1(1):13-20.

13.

Designing the epitope flanking regions for optimal generation of CTL epitopes.

Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

Vaccine. 2014 Jun 12;32(28):3509-16. doi: 10.1016/j.vaccine.2014.04.039. Epub 2014 May 2.

PMID:
24795226
14.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

15.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

16.

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS; MOPH TAVEG Collaboration.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57. doi: 10.1089/aid.2012.0103. Epub 2012 Oct 4.

17.

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.

Steers NJ, Ratto-Kim S, de Souza MS, Currier JR, Kim JH, Michael NL, Alving CR, Rao M.

PLoS One. 2012;7(8):e42579. doi: 10.1371/journal.pone.0042579. Epub 2012 Aug 6.

18.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.

Eller MA, Eller LA, Ratto-Kim S, Ouma BJ, Lo V, de Souza M, Guwatudde D, Nails B, Michael NL, Wabwire-Mangen F, Robb ML, Marovich MA, Sandberg JK, Currier JR.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):9-18. doi: 10.1097/QAI.0b013e31825c1217.

PMID:
22580564
19.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.

20.

OMIP-007: phenotypic analysis of human natural killer cells.

Eller MA, Currier JR.

Cytometry A. 2012 Jun;81(6):447-9. doi: 10.1002/cyto.a.22033. Epub 2012 Mar 12. No abstract available.

21.

Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.

Currier JR, Robb ML, Michael NL, Marovich MA.

J Transl Med. 2011 Dec 8;9:212. doi: 10.1186/1479-5876-9-212.

22.

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA.

PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16.

23.

Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans.

Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, Laeyendecker O, Quinn TC, Kiwanuka N, Serwadda D, Sewankambo NK, Tasseneetrithep B, Wawer MJ, Gray RH, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

PLoS One. 2011 Apr 19;6(4):e18779. doi: 10.1371/journal.pone.0018779.

24.

Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif.

Eller MA, Koehler RN, Kijak GH, Eller LA, Guwatudde D, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Virol. 2011 May;85(10):4802-11. doi: 10.1128/JVI.00111-11. Epub 2011 Mar 16.

25.

Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Steers NJ, Currier JR, Kijak GH, di Targiani RC, Saxena A, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

J Virol. 2011 Feb;85(4):1541-53. doi: 10.1128/JVI.01790-10. Epub 2010 Nov 24.

26.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

27.

Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.

Koehler RN, Walsh AM, Saathoff E, Tovanabutra S, Arroyo MA, Currier JR, Maboko L, Hoelscher M, Robb ML, Michael NL, McCutchan FE, Kim JH, Kijak GH.

J Infect Dis. 2010 Nov 15;202(10):1562-6. doi: 10.1086/656913. Epub 2010 Oct 5. Erratum in: J Infect Dis. 2011 Mar;203(5):749. Hoelsher, Michael [corrected to Hoelscher, Michael].

PMID:
20923372
28.

High-throughput high-resolution class I HLA genotyping in East Africa.

Koehler RN, Walsh AM, Sanders-Buell EE, Eller LA, Eller M, Currier JR, Bautista CT, Wabwire-Mangen F, Hoelscher M, Maboko L, Kim J, Michael NL, Robb ML, McCutchan FE, Kijak GH.

PLoS One. 2010 May 20;5(5):e10751. doi: 10.1371/journal.pone.0010751.

29.

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A.

Cancer Immunol Immunother. 2010 Apr;59(4):609-18. doi: 10.1007/s00262-009-0788-2. Epub 2009 Nov 6.

30.

High-throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real-time PCR.

Koehler RN, Walsh AM, Moqueet N, Currier JR, Eller MA, Eller LA, Wabwire-Mangen F, Michael NL, Robb ML, McCutchan FE, Kijak GH.

Tissue Antigens. 2009 Jul;74(1):73-80. doi: 10.1111/j.1399-0039.2009.01265.x.

PMID:
19522772
31.

Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection.

Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, Guwatudde D, McCutchan FE, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):380-9. doi: 10.1097/QAI.0b013e3181aa256e.

PMID:
19487954
32.

HLA class I allele and haplotype diversity in Ugandans supports the presence of a major east African genetic cluster.

Kijak GH, Walsh AM, Koehler RN, Moqueet N, Eller LA, Eller M, Currier JR, Wang Z, Wabwire-Mangen F, Kibuuka HN, Michael NL, Robb ML, McCutchan FE.

Tissue Antigens. 2009 Mar;73(3):262-9. doi: 10.1111/j.1399-0039.2008.01192.x.

PMID:
19254258
33.

Spectratype/immunoscope analysis of the expressed TCR repertoire.

Currier JR, Robinson MA.

Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.28. doi: 10.1002/0471142735.im1028s38. Review.

PMID:
18432693
34.

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Currier JR, Galley LM, Wenschuh H, Morafo V, Ratto-Kim S, Gray CM, Maboko L, Hoelscher M, Marovich MA, Cox JH.

Clin Vaccine Immunol. 2008 Feb;15(2):267-76. Epub 2007 Dec 12.

35.

A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection.

Geldmacher C, Gray C, Nason M, Currier JR, Haule A, Njovu L, Geis S, Hoffmann O, Maboko L, Meyerhans A, Cox J, Hoelscher M.

J Virol. 2007 Dec;81(24):13809-15. Epub 2007 Sep 26.

36.

Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses.

Rutebemberwa A, Bess JW Jr, Brown B, Arroyo M, Eller M, Slike B, Polonis V, McCutchan F, Currier JR, Birx D, Robb M, Marovich M, Lifson JD, Cox JH.

AIDS Res Hum Retroviruses. 2007 Apr;23(4):532-42.

PMID:
17506610
37.

In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype.

Geldmacher C, Currier JR, Gerhardt M, Haule A, Maboko L, Birx D, Gray C, Meyerhans A, Cox J, Hoelscher M.

AIDS. 2007 Jan 11;21(2):135-43.

PMID:
17197803
38.

CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients.

Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, Williamson C, Birx D, Meyerhans A, Cox J, Hoelscher M.

J Virol. 2007 Mar;81(5):2440-8. Epub 2006 Dec 20.

39.

Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2.

Visawapoka U, Tovanabutra S, Currier JR, Cox JH, Mason CJ, Wasunna M, Ponglikitmongkol M, Dowling WE, Robb ML, Birx DL, McCutchan FE.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):695-702.

PMID:
16831094
41.

HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides.

Rutebemberwa A, Currier JR, Jagodzinski L, McCutchan F, Birx D, Marovich M, Cox JH.

AIDS. 2005 Jul 22;19(11):1165-72.

PMID:
15990569
42.

Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians.

Currier JR, Harris ME, Cox JH, McCutchan FE, Birx DL, Maayan S, Ferrari G.

AIDS Res Hum Retroviruses. 2005 Mar;21(3):239-45.

PMID:
15795531
43.

HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians.

Ferrari G, Currier JR, Harris ME, Finkelstein S, de Oliveira A, Barkhan D, Cox JH, Zeira M, Weinhold KJ, Reinsmoen N, McCutchan F, Birx DL, Osmanov S, Maayan S.

Hum Immunol. 2004 Jun;65(6):648-59.

PMID:
15219385
44.

Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance.

Kijak GH, Currier JR, Tovanabutra S, Cox JH, Michael NL, Wegner SA, Birx DL, McCutchan FE.

AIDS Rev. 2004 Jan-Mar;6(1):54-60. Review.

PMID:
15168741
45.

Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans.

Currier JR, Dowling WE, Wasunna KM, Alam U, Mason CJ, Robb ML, Carr JK, McCutchan FE, Birx DL, Cox JH.

AIDS. 2003 Oct 17;17(15):2149-57.

PMID:
14523271
46.

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.

Marovich MA, Mascola JR, Eller MA, Louder MK, Caudrelier PA, El-Habib R, Ratto-Kim S, Cox JH, Currier JR, Levine BL, June CH, Bernstein WB, Robb ML, Schuler-Thurner B, Steinman RM, Birx DL, Schlesinger-Frankel S.

J Infect Dis. 2002 Nov 1;186(9):1242-52. Epub 2002 Oct 7.

PMID:
12402193
48.

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH.

J Immunol Methods. 2002 Feb 1;260(1-2):157-72.

PMID:
11792386
49.

Molecular cloning and sequencing of cDNA encoding eight new rhesus macaque TCRBV gene families.

Currier JR, Stevenson KS, Robinson MA.

Immunogenetics. 2000 Apr;51(4-5):387-91. No abstract available.

PMID:
10803854
50.

Contributions of CD4+, CD8+, and CD4+CD8+ T cells to skewing within the peripheral T cell receptor beta chain repertoire of healthy macaques.

Currier JR, Stevenson KS, Kehn PJ, Zheng K, Hirsch VM, Robinson MA.

Hum Immunol. 1999 Mar;60(3):209-22.

PMID:
10321957

Supplemental Content

Loading ...
Support Center